Online citations, reference lists, and bibliographies.

MiR-134, Epigenetically Silenced In Gliomas, Could Mitigate The Malignant Phenotype By Targeting KRAS

Z. Wang, C. Zhang, Z. Wang, X. Meng, Xiaojuan Liu, B. Han, Chunbin Duan, J. Cai, Zhong-fei Hao, M. Chen, T. Jiang, Y. Li, C. Jiang, Hong-jun Wang
Published 2018 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Gliomas are characterized by a malignant phenotype with proliferation, cell cycle arrest and invasion. To explore the biological consequences of epigenetically regulated miRNAs, we performed a microarray-based screening (whose expression was affected by 5-AZA treatment) followed by bisulfite sequencing validation. We found that miR-134 as an epigenetically regulated suppressor gene with prognostic value in gliomas. MicroRNA-134 was downregulated in high-grade gliomas, especially in GBM samples. Functional studies in vitro and in vivo in mouse models showed that overexpression of miR-134 was sufficient to reduce cell cycle arrest, cell proliferation and invasion. Target analysis and functional assays correlated the malignant phenotype with miR-134 target gene KRAS, an established upstream regulator of ERK and AKT pathways. Overall, our results highlighted a role for miR-134 in explaining the malignant phenotype of gliomas and suggested its relevance as a target to develop for early diagnostics and therapy.
This paper references
10.1016/j.ccell.2017.07.007
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
B. Raphael (2017)
10.1158/0008-5472.CAN-15-1770
miR-892b Silencing Activates NF-κB and Promotes Aggressiveness in Breast Cancer.
L. Jiang (2016)
10.1158/0008-5472.CAN-06-4218
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.
Amaia Lujambio (2007)
R: A language and environment for statistical computing.
R. Team (2014)
10.1038/nature03702
MicroRNA expression profiles classify human cancers
J. Lu (2005)
10.1073/pnas.1502068112
MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer
Ri Cui (2015)
10.1038/nature04367
A brain-specific microRNA regulates dendritic spine development
G. Schratt (2006)
10.1159/000068621
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
R. Hilger (2002)
10.1089/dna.2014.2629
miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Yiyang Liu (2015)
10.1158/0008-5472.CAN-14-1439
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
S. Tao (2014)
10.1371/journal.pone.0087665
Genome-Wide Screening Identified That miR-134 Acts as a Metastasis Suppressor by Targeting Integrin β1 in Hepatocellular Carcinoma
Ruopeng Zha (2014)
10.1093/carcin/bgt356
Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling.
C. Wang (2014)
10.1038/nature21386
Integrated genomic and molecular characterization of cervical cancer
R. Burk (2017)
10.1073/PNAS.0510565103
A microRNA expression signature of human solid tumors defines cancer gene targets
S. Volinia (2006)
10.1111/jcmm.12889
miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor
Q. Qin (2016)
10.1093/carcin/bgu030
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
M. Guo (2014)
10.1016/j.ccell.2015.12.005
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.
J. Hu (2016)
Hepatocyte nuclear factor - 4 α reverses malignancy of hepatocellular carcinoma through regulating miR - 134 in the DLK 1 - DIO 3 region
M. Ramachandran (2017)
10.3892/ol.2017.5644
MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.
Xiaomei Su (2017)
MicroRNAs: genomics, biogenesis
D. P. Bartel (2004)
10.1016/j.cell.2007.06.009
AKT/PKB Signaling: Navigating Downstream
B. Manning (2007)
10.3892/ijo.2013.1844
MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression
Chao-Shi Niu (2013)
MicroRNA-134 functions as a tumor suppressor gene in gastric cancer.
Ze-An Qiu (2016)
10.1016/j.ccell.2017.02.010
Integrated Molecular Characterization of Uterine Carcinosarcoma.
A. Cherniack (2017)
10.1038/nrclinonc.2009.111
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
N. Normanno (2009)
10.1093/carcin/bgs212
DNA methylation of microRNA genes in multiple myeloma.
K. Wong (2012)
10.1038/NRG1379
MicroRNAs: small RNAs with a big role in gene regulation
L. He (2004)
10.1016/j.ccr.2010.03.017
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
H. Noushmehr (2010)
10.1073/pnas.1317026110
Evolutionary etiology of high-grade astrocytomas
Y. Song (2013)
10.1007/s13277-016-5027-9
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Yuguang Zhao (2016)
10.1002/stem.185
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells.
Maureen M. Sherry (2009)
10.1200/JCO.2016.67.6940
Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility.
Nardin Samuel (2016)
10.1073/pnas.1114033109
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
N. Szerlip (2012)
10.1158/1078-0432.CCR-16-0925
Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus
M. Ramachandran (2016)
10.1111/j.1755-5949.2012.00344.x
MicroRNA‐21 Expression is regulated by β‐catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK
L. Han (2012)
10.1016/j.canlet.2012.12.024
Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.
Y. Wang (2013)
10.1002/hep.26573
Hepatocyte nuclear factor‐4α reverses malignancy of hepatocellular carcinoma through regulating miR‐134 in the DLK1‐DIO3 region
C. Yin (2013)
10.1158/0008-5472.CAN-15-0390
Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression.
Sandeep K. Botla (2016)
10.1038/ng.3273
Mutational landscape and clonal architecture in grade II and III gliomas
H. Suzuki (2015)
10.1016/j.canlet.2017.03.002
miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
F. Yang (2017)
10.1038/srep13072
Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma
H. Wang (2015)
10.1007/s13277-014-2283-4
MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R
Tianzhu Guo (2014)
10.1371/journal.pone.0020600
MicroRNA and Target Protein Patterns Reveal Physiopathological Features of Glioma Subtypes
Elodie Lages (2011)
10.1158/0008-5472.CAN-15-3367
miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis.
C. Tellez (2016)
10.1007/s00401-007-0239-0
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations
J. Jeuken (2007)
10.1038/cdd.2013.196
Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma
Y. Zhang (2014)
10.1016/S0092-8674(04)00045-5
MicroRNAs Genomics, Biogenesis, Mechanism, and Function
D. Bartel (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar